Scrapie

Scrapie is a fatal, degenerative neurological disease of sheep and goats caused by abnormal prion proteins that accumulate in the brain and other tissues. As the oldest known transmissible spongiform encephalopathy, scrapie has been recognized in sheep for over two hundred fifty years and serves as the prototypical prion disease from which understanding of bovine spongiform encephalopathy and similar conditions has been derived. The disease produces progressive neurological dysfunction over months, invariably resulting in death, with no effective treatment or cure available despite extensive research efforts.

Scrapie occurs in sheep populations worldwide, though aggressive eradication programs have eliminated or significantly reduced the disease in several countries. The condition affects both sheep and goats, with sheep representing the primary host species historically associated with the disease. Prevalence varies enormously between countries and regions depending on genetic selection practices, surveillance intensity, and eradication program effectiveness. Flocks with genetic susceptibility and historical exposure may experience significant losses, while those with resistant genetics or no exposure history remain free of disease.

The economic and regulatory impact of scrapie extends far beyond direct animal losses. As a reportable disease in most countries, detection of scrapie triggers mandatory control measures including movement restrictions, enhanced surveillance, and often depopulation of affected flocks. International trade in sheep and goat genetics is heavily influenced by scrapie status, with importing countries requiring extensive testing and certification. The association with other prion diseases, particularly the concern over potential connections to human disease, has driven intensive public health and agricultural policy attention to scrapie surveillance and control.

Scrapie represents a unique challenge in animal health because the causative agent is not a conventional pathogen but rather a misfolded protein that resists standard disinfection procedures and persists in the environment for extended periods. No vaccine exists to prevent infection, and no treatment can halt disease progression once clinical signs appear. Control efforts therefore focus on genetic selection for resistant sheep, surveillance to identify affected flocks, and management practices to reduce transmission. Understanding scrapie biology, recognizing clinical signs, and implementing prevention strategies are essential responsibilities for sheep producers and veterinarians involved in ovine health management.

The primary cause of scrapie is infection with abnormal prion proteins, designated PrPSc, that induce normal cellular prion proteins in the host to adopt the same misfolded configuration. Unlike conventional infectious agents, prions contain no nucleic acid and consist entirely of protein. The abnormal prion protein acts as a template, converting normal PrPC proteins to the disease-associated form in a cascade that progressively accumulates throughout susceptible tissues. This accumulation of misfolded protein in brain tissue produces the characteristic spongy degeneration and neurological dysfunction of clinical scrapie.

Genetic factors profoundly influence susceptibility to scrapie through variations in the prion protein gene that affect how readily normal proteins convert to the abnormal form. The ovine prion protein gene contains several polymorphic codons, with variations at codons 136, 154, and 171 having the greatest impact on scrapie susceptibility. Sheep carrying specific alleles, particularly those encoding glutamine at codon 171, show high susceptibility to classical scrapie, while those with arginine at this position demonstrate significant resistance. This genetic basis has enabled development of breeding programs to reduce flock susceptibility and forms the foundation of many national scrapie eradication efforts.

Environmental contamination represents a major transmission route for scrapie, with prions shed in placental tissues, fetal fluids, and other materials from infected sheep persisting in soil and on equipment for years. Lambing areas become particularly contaminated when infected ewes give birth, exposing susceptible animals through ingestion of contaminated materials. Prions resist standard disinfection, ultraviolet light, and environmental degradation processes that inactivate conventional pathogens, allowing long-term environmental persistence. This environmental stability complicates disease control, as previously infected premises may harbor infectious material indefinitely.

Risk factors for scrapie development combine genetic susceptibility with exposure to infectious prions. Sheep with susceptible genotypes in flocks or on premises where scrapie has occurred face the highest risk. Maternal transmission from infected ewes to lambs, through both prenatal exposure and contact with contaminated birth materials, represents an efficient route of natural spread. Purchase of animals from infected flocks or with unknown history introduces risk to previously clean premises. Close contact between susceptible animals and those incubating infection allows horizontal transmission. Age influences disease expression, with clinical signs typically appearing in sheep between two and five years of age following incubation periods of several years.

The pathophysiology of scrapie involves progressive accumulation of abnormal prion protein in the central nervous system and lymphoid tissues. Initial replication likely occurs in gut-associated lymphoid tissue following oral exposure, with subsequent spread through the peripheral nervous system to the brain. Once in the central nervous system, PrPSc accumulation causes neuronal vacuolation producing the characteristic spongiform appearance, gliosis, and neuronal loss. Different strains of scrapie prions produce varying patterns of brain lesions and clinical presentations, with classical scrapie being the most commonly recognized form. Atypical scrapie, a distinct prion strain discovered through active surveillance, produces different patterns of brain lesions and occurs sporadically even in sheep with genotypes resistant to classical scrapie.

Early warning signs of scrapie are subtle and easily overlooked, often initially attributed to other causes or dismissed as individual behavioral variation. Affected sheep may show minor changes in behavior, including increased nervousness, alterations in flock position, or slight changes in gait that producers familiar with individual animals might notice but not immediately associate with serious disease. Early coat changes, with wool appearing dull or harsh, may precede more obvious signs. Weight loss despite adequate nutrition sometimes provides the first indication that something is wrong with an individual animal.

Common symptoms of scrapie reflect the progressive neurological damage characteristic of prion diseases. Pruritus, or intense itching, represents one of the most recognizable signs and gives the disease its name from the characteristic scraping of affected sheep against fences, posts, and other objects to relieve the sensation. The rubbing and scratching produces wool loss with characteristic patterns over the rump, flanks, and shoulders. Not all scrapie cases show pruritus, and reliance on this sign alone misses cases presenting primarily with other symptoms. The nibble reflex, where scratching along the back triggers an exaggerated lip-smacking response with head extension, often accompanies pruritis and aids clinical diagnosis.

Behavioral changes in sheep with scrapie include increased excitability, anxiety, and abnormal reactions to normal stimuli. Affected animals may appear nervous or apprehensive, showing exaggerated startle responses to sounds or movement. Separation from the flock, either through choice or inability to keep up, becomes increasingly common. Changes in temperament, with previously calm animals becoming aggressive or vice versa, reflect progressive brain damage. Disorientation and apparent blindness or impaired vision may develop. Some affected sheep show depression rather than excitability, becoming dull and unresponsive to their environment.

Physical signs of scrapie include progressive weight loss that continues despite adequate feed intake and absence of other obvious illness. Affected sheep develop characteristic gait abnormalities that worsen over time, often described as a high-stepping or bunny-hopping gait in the hind legs. Incoordination progresses from subtle instability to obvious ataxia affecting all four limbs. Tremors, particularly of the head and neck, may be visible at rest or become apparent when the animal is stressed or restrained. General weakness develops, with affected animals showing difficulty rising and maintaining posture. The fleece becomes increasingly damaged from rubbing, with wool loss and skin damage in characteristic patterns.

Symptom progression in scrapie follows an inexorable downward course over weeks to months once clinical signs appear. Initial subtle signs progress to obvious neurological dysfunction that makes affected animals readily identifiable. Weight loss accelerates as the disease advances, and affected sheep become increasingly unable to compete for resources or maintain normal activities. Recumbency eventually develops as weakness and incoordination prevent ambulation. The duration of clinical disease varies from two weeks to six months or longer, with most cases progressing to terminal stages within two to four months of obvious symptom onset.

Emergency symptoms requiring immediate attention in suspected scrapie cases involve recognition that the condition is reportable and affected animals must not enter the food chain. Any sheep showing progressive neurological disease with pruritus and weight loss should be immediately reported to regulatory veterinary authorities. Severely affected animals unable to rise or showing extreme distress require prompt humane euthanasia followed by proper sample collection for diagnostic confirmation. Suspected cases should be isolated from other sheep to prevent potential transmission pending investigation. Contact with regulatory officials provides guidance on appropriate handling of suspects.

Clinical examination of suspected scrapie cases involves careful assessment of neurological function combined with evaluation of the characteristic pruritus and physical changes. The nibble reflex test, performed by vigorously scratching along the dorsal midline and observing for the exaggerated lip movements and head extension, provides supportive evidence when positive. Evaluation of gait, coordination, and postural reactions documents neurological deficits. Body condition scoring quantifies weight loss severity. The combination of clinical signs with appropriate history, including animal age, genotype if known, and flock scrapie history, guides diagnostic suspicion. Clinical diagnosis alone is insufficient for regulatory purposes, and laboratory confirmation is required.

Diagnostic tests for scrapie have evolved substantially with advances in prion detection technology. Definitive diagnosis requires demonstration of abnormal prion protein in brain tissue through immunohistochemistry or Western blot analysis of samples collected at necropsy. The obex region of the brainstem provides the primary diagnostic sample for classical scrapie. Live animal testing using biopsy of lymphoid tissue from the third eyelid or rectal mucosa can detect PrPSc in preclinical sheep with susceptible genotypes, though sensitivity is lower than brain examination. Genetic testing identifies the prion protein genotype, informing both individual susceptibility assessment and flock management decisions.

Differential diagnosis of scrapie must consider other causes of chronic neurological disease and pruritus in adult sheep. Listeriosis produces neurological signs but typically has acute onset, affects brainstem function asymmetrically, and may respond to antibiotic therapy. Pregnancy toxemia causes neurological dysfunction but occurs specifically in late-gestation ewes with metabolic derangement. Lice and other external parasites cause pruritus without neurological involvement. Louping ill and other viral encephalitides produce neurological disease but may show fever and respond partially to supportive care. Spinal cord compression from vertebral abscesses or degenerative conditions causes progressive hindlimb dysfunction. Thorough diagnostic evaluation including necropsy examination helps distinguish scrapie from conditions with potentially better outcomes.

Herd-level diagnostics for scrapie involve surveillance activities to detect infection throughout a flock and assess risk levels. Targeted sampling of sheep dying or culled for any reason provides surveillance through slaughter or mortality monitoring programs. Whole-flock genotyping identifies the distribution of susceptible and resistant animals. Testing of sheep identified as high-risk based on genotype or flock history provides additional case detection. Investigation of affected flocks includes trace-back and trace-forward activities to identify source of infection and potential spread to other premises. National surveillance programs combine regulatory testing requirements with voluntary genotyping and monitoring to detect scrapie and track eradication progress.

Emergency treatment options for scrapie do not exist because no therapy can halt or reverse prion disease progression. Once clinical signs develop, the disease invariably progresses to death regardless of any interventions attempted. Supportive care may temporarily improve comfort but does not alter outcomes. The primary emergency decision involves recognizing suspected cases and ensuring proper reporting to regulatory authorities. Affected animals should be humanely euthanized to prevent suffering once the diagnosis is established or strongly suspected, with appropriate sample collection for laboratory confirmation.

Medical management of scrapie is not possible in any meaningful sense, as the abnormal prion proteins cannot be cleared or neutralized by any known pharmaceutical approach. Research has explored numerous potential therapies including antiprion compounds, immunotherapies, and other experimental approaches, but none has demonstrated clinical efficacy. The unique nature of prion agents, lacking nucleic acids and resisting standard antimicrobial approaches, presents fundamental barriers to treatment development. Animals diagnosed with scrapie should be euthanized humanely rather than subjected to ineffective treatment attempts that prolong suffering.

Surgical intervention has no application in scrapie management, as the disease process is diffusely distributed throughout the nervous system and cannot be addressed through surgical approaches. Brain or nervous system surgery cannot remove or correct the underlying pathology. The only procedural aspects of scrapie case management involve proper sample collection from euthanized animals for diagnostic confirmation and disposal of carcasses according to regulatory requirements.

Supportive care for sheep with scrapie focuses on maintaining comfort until euthanasia is performed rather than attempting to prolong survival. Providing easily accessible feed and water, protecting affected animals from flock competition, and maintaining clean dry housing helps maintain basic welfare. Severely pruritic animals may obtain temporary relief from anti-inflammatory medications, though this does not alter disease progression. The ethical approach to confirmed or strongly suspected scrapie cases prioritizes humane euthanasia over prolonged survival with progressive neurological deterioration.

Herd treatment protocols following scrapie diagnosis focus on flock management rather than individual animal treatment. Genotyping remaining flock members identifies those with susceptible genotypes requiring removal and those with resistant genetics that can potentially remain. Quarantine restrictions prevent movement of sheep from affected premises pending completion of investigation and cleanup activities. Cleaning and disinfection protocols, while challenged by prion environmental resistance, reduce contamination levels. Replacement of susceptible breeding stock with animals of resistant genotype gradually improves flock genetic profile. These measures address population-level disease control since individual treatment is not possible.

Treatment decisions in scrapie cases are fundamentally regulatory and management decisions rather than clinical treatment choices. Producers must work with regulatory veterinarians to fulfill reporting requirements, comply with movement restrictions, and implement mandated control measures. Decisions about flock depopulation versus genetic selection and monitored cleanup depend on regulatory programs in effect, flock genetic composition, and producer circumstances. The goal shifts from saving affected individuals to protecting remaining animals, eliminating infection from the premises, and preventing spread to other flocks.

Recovery from scrapie does not occur, as the disease is invariably fatal in affected individuals. Once clinical signs appear and progress to recognizable disease, survival times range from weeks to months, but no sheep recovers from established scrapie. The irreversible nature of prion-induced brain damage prevents recovery regardless of supportive care or time. This absolute prognosis distinguishes scrapie from other neurological conditions where treatment and recovery may be possible.

Post-diagnosis management focuses on flock recovery from the disease incursion rather than individual animal recovery. Flocks affected by scrapie face extended periods of quarantine and monitoring before regaining disease-free status. Requirements vary by regulatory jurisdiction but typically involve multiple years of surveillance, genetic testing, and negative findings before restrictions are lifted. The timeline for flock status recovery depends on control program requirements, genetic composition of remaining animals, and ongoing surveillance results.

Prognosis for flocks affected by scrapie depends on the genetic susceptibility profile of the flock and the completeness of control measure implementation. Flocks with predominantly susceptible genetics facing their first outbreak may experience additional cases over subsequent years as animals in the incubation phase develop clinical disease. Replacement of susceptible animals with resistant genotypes progressively reduces flock-level risk. Premises contamination may pose ongoing hazards that are difficult to fully eliminate. Complete flock depopulation followed by premises cleanup and repopulation with resistant genetics offers the most certain path to scrapie-free status but involves substantial economic impact.

Return to production considerations following scrapie occurrence involve rebuilding both flock health status and market access. Regulatory restrictions may limit or prohibit sales of breeding stock until the flock regains certified scrapie-free status. Show and exhibition participation may be restricted. Export certification requirements may be impossible to meet for extended periods. Insurance and indemnity programs may partially offset losses during the control and recovery period. Long-term flock recovery requires commitment to ongoing surveillance, genetic selection, and biosecurity measures that prevent reintroduction.

Vaccination protocols for scrapie do not exist, as no vaccine has been developed that provides protection against prion infection. The unique biology of prions, lacking the nucleic acid targets of conventional vaccines and consisting of host-derived proteins, presents fundamental challenges to vaccine development. Research efforts continue to explore potential immunization strategies, but no practical vaccine is available or anticipated in the near term. Prevention relies entirely on genetic selection and management practices rather than immunization.

Biosecurity measures represent critical components of scrapie prevention despite the unusual nature of the pathogen. Maintaining closed flocks that do not introduce animals from outside sources eliminates the primary route of disease introduction. When sheep must be purchased, selecting animals from scrapie-free certified flocks or the National Scrapie Eradication Program enrolled flocks reduces risk. Verifying resistant genotypes in purchased animals provides additional protection. Avoiding exposure to premises with scrapie history, including shared grazing land, exhibition facilities, and transport equipment, reduces environmental exposure risk. Isolation of purchased animals before flock introduction allows observation for signs of disease.

Genetic prevention through selection for scrapie-resistant genotypes provides the most effective tool for reducing flock susceptibility. Testing breeding stock for prion protein genotype identifies susceptible and resistant individuals. Selective breeding that eliminates susceptible alleles, particularly those encoding glutamine at codon 171, while increasing resistant alleles progressively improves flock genetic resistance. Many national scrapie programs promote or require genotype testing and selection as core elements of eradication strategy. Complete replacement of susceptible animals with those homozygous for resistant alleles virtually eliminates classical scrapie risk.

Management practices supporting scrapie prevention focus on lambing hygiene and environmental contamination control. Prompt removal and proper disposal of placental tissues and aborted fetuses eliminates a major source of environmental prion contamination. Avoiding communal lambing areas that accumulate contamination over multiple seasons reduces exposure of susceptible animals. Cleaning and disinfection of lambing facilities between uses, while not eliminating all prion contamination, reduces infectious load. Management of colostrum and milk to avoid potential transmission from infected ewes to susceptible lambs may provide additional protection.

Quarantine and testing protocols form the foundation of organized scrapie control programs. Flocks enrolled in voluntary or mandatory certification programs demonstrate freedom from infection through ongoing surveillance and testing. Purchase of animals only from certified scrapie-free sources reduces introduction risk. Traceability systems that document animal movements support investigation when cases are detected. Testing requirements for interstate or international movement verify individual and flock status. Participation in national eradication programs provides both disease status verification and access to indemnity programs if infection is detected.

Daily management and monitoring for scrapie in at-risk flocks requires ongoing vigilance for early clinical signs in susceptible animals. Regular observation of sheep behavior, condition, and coat quality during routine management activities provides opportunities to detect subtle early changes. Particular attention to mature sheep between two and five years old, the age range when clinical disease most commonly appears, focuses monitoring efforts appropriately. Any sheep showing unexplained weight loss, behavioral changes, or the characteristic pruritus and rubbing should be evaluated promptly for possible scrapie.

Housing and environmental management considerations for scrapie prevention focus on minimizing accumulation and exposure to environmental prion contamination. Designing lambing facilities for easy cleaning between uses and avoiding use of the same areas year after year reduces contamination buildup. Providing adequate space prevents crowding that increases contact and transmission opportunities. Managing grazing to avoid areas known or suspected to be contaminated from previous scrapie cases protects susceptible animals. Proper disposal of dead sheep and all birth tissues through incineration or approved rendering eliminates contamination sources.

Herd health programs addressing scrapie integrate genetic testing, surveillance, and biosecurity into comprehensive prevention strategies. Whole-flock genotyping provides baseline information on susceptibility distribution and guides breeding decisions. Annual review of genotype testing results and breeding plans ensures progress toward improved genetic resistance. Surveillance protocols including testing of all mature sheep dying or culled for any reason detect subclinical infection. Participation in national certification programs demonstrates flock status and provides marketing advantages for breeding stock.

Record keeping and monitoring systems for scrapie management must document genetics, movements, and health observations over extended timeframes corresponding to the disease's long incubation period. Individual animal genotype results should be maintained and used in breeding decisions. Movement records documenting all animals entering or leaving the premises support traceability if cases are detected. Health observation records noting any suspicious signs, even if ultimately attributed to other causes, provide historical context for investigation. Diagnostic test results from surveillance activities confirm ongoing flock freedom from infection.

Economic considerations for scrapie management include both the costs of prevention activities and the potentially catastrophic consequences of disease occurrence. Genotype testing costs, while representing an investment, are modest compared to the potential losses from scrapie outbreaks including animal value, market access restrictions, and control costs. Premium prices for certified scrapie-free breeding stock and animals with resistant genotypes offset testing expenses. Insurance or indemnity programs provide partial protection against losses if disease occurs. The economic analysis strongly favors investment in prevention given the absence of treatment options and severe consequences of infection.

High-risk breeds for scrapie are those in which susceptible prion protein genotypes occur at high frequencies, though all sheep breeds can potentially carry susceptible alleles. Suffolk sheep historically showed high scrapie susceptibility, and this breed was disproportionately represented in scrapie case reports before genetic selection programs reduced susceptible allele frequency. Other breeds with documented susceptibility issues include Hampshire, Cheviot, and certain Merino lines. However, genetic selection over recent decades has substantially changed allele frequencies in many breed populations, making current breed-level risk assessments less reliable than individual genotype testing.

Production type considerations for scrapie risk relate more to management practices and genetic selection emphasis than to production system per se. Purebred breeding flocks maintaining specific bloodlines face risk if those lines carry susceptible genetics. Commercial flocks with high turnover and diverse genetics may have variable risk depending on ram sources and selection criteria. Show flocks with potential exposure at exhibitions and contact with animals from multiple sources face introduction risk. Export breeding operations must meet stringent scrapie testing and certification requirements regardless of production type. All production systems benefit from genetic selection for resistance as a component of breeding programs.

Genetic selection and testing provide the primary tools for managing scrapie risk at both individual and breed levels. Testing for prion protein genotype is widely available and relatively inexpensive, allowing informed selection decisions. Breeding organizations for most sheep breeds now track and publish genotype information for registered animals. National scrapie eradication programs encourage or require genotype testing as a condition of certification. Selection for the ARR allele, encoding arginine at codons 136, 154, and 171, produces resistance to classical scrapie. Elimination of the VRQ allele, the most susceptible variant, from breeding populations is a priority in eradication efforts. The success of genetic selection is demonstrated by dramatically reduced scrapie incidence in countries with mandatory or voluntary selection programs.

Commonly co-occurring conditions with scrapie are uncommon because scrapie's long incubation period and relatively uncommon occurrence make coincident disease unusual. However, affected sheep may develop secondary problems related to their progressive debilitation. Weight loss and weakness predispose to metabolic conditions and reduce resistance to other infections. Wool loss and skin damage from rubbing may allow secondary bacterial skin infections. Recumbent animals in terminal stages risk pressure sores and aspiration pneumonia. The primary clinical importance is distinguishing scrapie from more treatable conditions rather than managing co-occurring diseases.

Conditions with similar symptoms requiring differentiation from scrapie include various causes of chronic neurological disease and pruritus in adult sheep. Listeriosis produces neurological signs but typically shows asymmetric brainstem involvement, fever, and acute rather than chronic progression. Pseudorabies, where it occurs, causes acute pruritus and neurological disease but progresses much more rapidly than scrapie. Chronic liver disease may cause neurological signs and weight loss. External parasites including lice and mites cause pruritus without neurological involvement and respond to parasiticide treatment. Vertebral abscess or spinal cord compression produces progressive hindlimb dysfunction. Brain tumors cause progressive neurological deficits. Definitive differentiation requires diagnostic testing including postmortem examination.

Complications and sequelae of scrapie relate primarily to the public health and regulatory dimensions of prion disease rather than clinical complications in affected animals. While no evidence links classical scrapie to human disease, concerns about transmissible spongiform encephalopathies and their potential interspecies transmission maintain regulatory attention on scrapie control. Atypical scrapie, a distinct prion strain, may have different biological properties and requires separate consideration. Premises contamination following scrapie cases persists for unknown but potentially extended periods, complicating repopulation and creating ongoing risk. The regulatory consequences of scrapie detection, including quarantine, movement restrictions, and potential depopulation, may be more immediately impactful than the clinical disease itself.